Skip to main content
SpringerLink
Log in

Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Inflammation has been associated with atherosclerotic cardiovascular disease (CVD) and anemia in patients with end-stage renal disease (ESRD) which may lead to left ventricular impairment via myocardial hypertrophy and/or ischemia. We therefore sought to investigate serum levels of sFas in uremic patients and its correlation with known markers of inflammation and CVD.

Methods

The study included 30 patients on hemodialysis, 30 patients with chronic kidney disease (CKD), and 30 normal control subjects. We measured serum levels of sFas, C-reactive protein (CRP), and albumin. We also investigated the association of serum sFas levels with the presence of CVD by echocardiographic assessment before and after 1 year.

Results

Levels of sFas were elevated in CKD and ESRD patients compared to controls. sFas levels correlated positively with serum creatinine and negatively with serum albumin. In the dialysis patients, we observed that sFas levels were higher among those with CVD. Compared with baseline, after 1 year of follow-up there was a significant decrease in left ventricular (LV) ejection fraction, increases in LV end-diastolic dimension and LV end-systolic dimension, and myocardial ischemic changes.

Conclusions

These results suggest that sFas may be a marker of inflammation in CKD and ESRD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Locatelli F, Marcelli D, Conte F, Leunissen K, Luno J, Chazot C. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant. 2001;15(Suppl 5):S69–80.

    Google Scholar 

  2. Petrosa G, Simone S, Soccio M, Marrone D, Gradaliano G. Chronic inflammation cardiovascular disease in hemodialysis. G Ital Nefrol. 2003;20(6):631–40.

    Google Scholar 

  3. Ridker PM, Hennekens CH, Burning JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med. 2000;342:836–43.

    Article  CAS  Google Scholar 

  4. Park CW, Shin YS, Kim CM, et al. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis. 2002;40(6):1340–1.

    Article  Google Scholar 

  5. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis. 2001;38:1343–50.

    Article  CAS  PubMed  Google Scholar 

  6. Cleveland JL, Ihle JN. The Fas and the cytoplasmic apoptosis. Cell. 1995;81:479–83.

    Article  CAS  PubMed  Google Scholar 

  7. Dalboni M, Sardenberg C, Andreoli M, et al. Soluble Fas. A novel marker of inflammation in uremia. Artif Organs. 2003;27(8):687–91.

    Article  CAS  PubMed  Google Scholar 

  8. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–83.

    CAS  PubMed  Google Scholar 

  9. Nagata S, Goldstein P. The Fas death factor. Science. 1995;25:1449–56.

    Article  Google Scholar 

  10. Perianayagam MC, Murray SL, Balakrishnan VS, et al. Serum soluble Fas (CD95) and Fas legend profiles in chronic kidney failure. J Lab Clin Med. 2000;136:320–7.

    Article  CAS  PubMed  Google Scholar 

  11. Santoro A, Mancini E. Cardiac effects of chronic inflammation in dialysis patients. Nephrol Dial Transplant. 2002;17(8):10–5.

    Article  PubMed  Google Scholar 

  12. Serneri GGN, Prisco D, Martini F, et al. Acute T-cell activation is detectable in unstable angina. Circulation. 1997;95:1806–12.

    Google Scholar 

  13. Okuyama M, Yamaguchi S, Nozaki N, Yamaoka M, Shirakabe M, Tomoike H. Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Am J Cardiol. 1997;79:01–1698.

    Google Scholar 

  14. Nishigaki K, Minatoguchi S, Seishima M, et al. Plasma Fas legend, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic heart failure. J Am Coll Cardiol. 1997;29:1214–20.

    Article  CAS  PubMed  Google Scholar 

  15. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol. 1992;148:1274–9.

    CAS  PubMed  Google Scholar 

  16. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561–6.

    Article  CAS  PubMed  Google Scholar 

  17. Cheng J, Zhou T, Liu C, Shapiro JP, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors acknowledge the staff members of the cardiac unit at Mansoura University, who helped to study and report the echocardiographic data.

Author information

Authors and Affiliations

  1. Urology and Nephrology Centre, University of Mansoura, Mansoura, Egypt

    Amgad E. El-Agroudy

  2. Medical Biochemistry Department, Faculty of Medicine, University of Mansoura, Mansoura, Egypt

    Ayman El-Baz

Authors
  1. Amgad E. El-Agroudy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayman El-Baz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amgad E. El-Agroudy.

About this article

Cite this article

El-Agroudy, A.E., El-Baz, A. Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients. Clin Exp Nephrol 14, 152–157 (2010). https://doi.org/10.1007/s10157-009-0261-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-009-0261-8

Keywords

Search

Navigation